Response evaluation with
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Breast
/ diagnostic imaging
Breast Neoplasms
/ diagnostic imaging
Disease Progression
Female
Fluorodeoxyglucose F18
Humans
Middle Aged
Piperazines
/ therapeutic use
Positron Emission Tomography Computed Tomography
Preliminary Data
Pyridines
/ therapeutic use
Radiopharmaceuticals
Retrospective Studies
Treatment Outcome
Whole Body Imaging
18F-FDG PET/CT
Breast cancer
Palbociclib
Response assessment
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
12
10
2018
accepted:
02
12
2018
pubmed:
21
12
2018
medline:
21
6
2019
entrez:
21
12
2018
Statut:
ppublish
Résumé
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor recently approved for treatment in advanced or metastatic breast cancer (BC) patients. The use of In 12 metastatic BC patients (mean age = 62 ± 10 years) treated with Palbociclib plus endocrine therapy and who underwent a baseline and post-therapy Compared to SRE, MRE increased the proportion of patients classified with progressive disease from 25 to 50% and differed from SRE in 8/12 patients: 3/8 shifted from stable disease or undetermined response to metabolic progression (more unfavorable category), 4/8 from stable disease to partial or complete metabolic response, and 1/8 from partial response to complete metabolic response (more favorable category). Additional PET/CT information led to a change in patients' management in 3/12 (25%) patients. In BC patients treated with Palbociclib, additional
Identifiants
pubmed: 30569442
doi: 10.1007/s12149-018-01323-8
pii: 10.1007/s12149-018-01323-8
doi:
Substances chimiques
Antineoplastic Agents
0
Piperazines
0
Pyridines
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
palbociclib
G9ZF61LE7G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM